Voxtur Announces Financial Results for the Q1 2025 – Ended March 31, 2025
www.sedarplus.ca
and at
www.voxtur.com
.
Financial Results:
1 Calculations include only the results from continuing operations and do not include results of discontinued operations. As at March 31, 2025, management was committed to a plan to sell one of the Company's business units. Accordingly, the Company has presented that business unit as a disposal group held for sale and reported its results as discontinued operations.
During the first quarter of 2025, revenue from continuing operations declined approximately $3.6 million and gross profit declined approximately $3 million compared to the same period in the prior year. Despite this, the Company's net loss from continuing operations remained relatively stable, underscoring the meaningful impact of realizing synergies across the organization and cost reduction measures implemented by management over the past several quarters.
Operational expense reductions initiated earlier this year began to positively impact the quarter, though the full benefit of these initiatives will be more fully realized in the second quarter and throughout the remainder of 2025.
Further discussion with respect to the financial results can be found in the Company's MD&A available at
www.sedarplus.ca
and at
www.voxtur.com
.
Management continues to work in close partnership with the Company's advisor and in conjunction with the Company's creditor as part of the strategic review announced earlier this year. The primary objective of this process is to reduce debt and position the Company for long-term financial stability and strength.
'We sincerely appreciate the continued support and patience of all our stakeholders as we navigate this important phase of our journey,' said Ryan Marshall, Voxtur's CEO. 'While we are not yet where we want to be, we are making steady progress, and our focus remains on building a more sustainable and resilient organization.'
The Company intends to host a shareholder call in the near future upon having material updates on the strategic review process and outline the path forward for the business, including other key corporate developments.
About Voxtur
Voxtur is a proptech company. The company offers targeted data analytics to simplify the multifaceted aspects of the lending lifecycle for investors, lenders, government agencies and servicers. Voxtur's proprietary data hub and workflow platforms more accurately and efficiently value real estate assets, providing critical due diligence that enables market participants to effectively originate, trade, or service defaults on mortgage loans. As an independent and transparent mortgage technology provider, the company offers primary and secondary market solutions in the United States and Canada. For more information, visit
www.voxtur.com
.
Forward-Looking Information
This news release contains certain forward-looking statements and forward-looking information (collectively, 'forward-looking information') which reflect the expectations of management regarding the Company's future growth, financial performance and objectives and the Company's strategic initiatives, plans, business prospects and opportunities. These forward-looking statements reflect management's current expectations regarding future events and the Company's financial and operating performance and speak only as of the date of this press release. By their very nature, forward-looking statements require management to make assumptions and involve significant risks and uncertainties, should not be read as guarantees of future events, performance or results, and give rise to the possibility that management's predictions, forecasts, projections, expectations or conclusions will not prove to be accurate, that the assumptions may not be correct and that the Company's future growth, financial performance and objectives and the Company's strategic initiatives, plans, business prospects and opportunities, including the duration, impact of and recovery from the COVID-19 pandemic, will not occur or be achieved. Any information contained herein that is not based on historical facts may be deemed to constitute forward-looking information within the meaning of Canadian and United States securities laws. Forward-looking information may be based on expectations, estimates and projections as at the date of this news release, and may be identified by the words 'may', 'would', 'could', 'should', 'will', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'expect' or similar expressions. Forward-looking information may include but is not limited to the anticipated financial performance of the Company and other events or conditions that may occur in the future. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the information is provided. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information include but are not limited to: additional costs related to acquisitions, integration of acquired businesses, and implementation of new products; changing global financial conditions, especially in light of the COVID-19 global pandemic; reliance on specific key employees and customers to maintain business operations; competition within the Company's industry; a risk in technological failure, failure to implement technological upgrades, or failure to implement new technological products in accordance with expected timelines; changing market conditions related to defaulted mortgage loans, and the failure of clients to send foreclosure and bankruptcy referrals in volumes similar to those prior to the COVID-19 global pandemic; failure of governing agencies and regulatory bodies to approve the use of products and services developed by the Company; the Company's dependence on maintaining intellectual property and protecting newly developed intellectual property; operating losses and negative cash flows; and currency fluctuations. Accordingly, readers should not place undue reliance on forward-looking information contained herein. Factors relating to the Company's financial guidance and targets disclosed in this press release include, in addition to the factors set out above, the degree to which actual future events accord with, or vary from, the expectations of, and assumptions used by, Voxtur's management in preparing the financial guidance and targets.
This forward-looking information is provided as of the date of this news release and, accordingly, is subject to change after such date. The Company does not assume any obligation to update or revise this information to reflect new events or circumstances except as required in accordance with applicable laws.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Voxtur's common shares are traded on the TSX Venture Exchange under the symbol VXTR and in the US on the OTCQB under the symbol VXTRF.
Company Contact:
Jordan Ross
Tel: (416)708-9764
jordan@voxtur.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
CULVER CITY, Calif., July 25, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Piper Sandler & Co. is acting as the exclusive placement agent for the registered direct offering. The securities to be sold by the Company are offered under its automatic shelf registration statement on Form S-3 (Registration No. 333-278770). A final prospectus supplement, which contains additional information relating to the offering, will be filed with the SEC and will be available on the SEC's website at Electronic copies of the prospectus supplement may be obtained for free by contacting Piper Sandler & Co., 350 North 5th Street, Suite 1300, Minneapolis, MN 55402, Attention: Prospectus Department, or by telephone at (800) 747-3924, or by email at prospectus@ Before investing in this offering, interested parties should read the prospectus supplement, the accompanying prospectus and the other documents that are incorporated by reference in such prospectus supplement and the accompanying prospectus in their entirety. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About ImmunityBio, Inc. ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the timing and size of the proposed offering, the potential exercise of the warrants being offered and resulting additional proceeds to the Company, the anticipated closing of the equity financing described herein and use of proceeds to be received from such financing, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that reduce or eliminate the need for standard high-dose chemotherapy. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) whether the equity financing transaction described herein will close on the timeline anticipated, if at all, (ii) those related to the regulatory submission, filing and review process and the timing thereof, (iii) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (iv) whether clinical trials will result in registrational pathways, (v) whether clinical trial data will be accepted by regulatory agencies, (vi) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vii) potential delays in product availability, regulatory approvals, and reimbursement decisions, (viii) ImmunityBio's ability to retain and hire key personnel, (ix) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (x) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xi) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law. View source version on Contacts Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio +1 Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
XPENG Launches Global Localization Strategy in Indonesia with First Locally-produced X9 Delivery
Indonesia has become the first country in the world where XPENG has localized its vehicle production. XPENG's Purwakarta factory rolled out the first locally produced X9 and delivered it to customer at the 2025 Gaikindo Indonesia International Auto Show (GIIAS). This milestone marks the official launch of XPENG's global localized manufacturing strategy, starting from Indonesia. XPENG New G6 made its debut at GIIAS 2025, featuring 800V architecture, 5C ultra-fast charging AI battery, which allows it to charge from 10% to 80% in just 12 minutes. JAKARTA, Indonesia, July 25, 2025 (GLOBE NEWSWIRE) -- XPENG Motors ("XPENG" or the "Company"; NYSE: XPEV, HKEX: 9868), a leading China-based high-tech company, marked a significant milestone by delivering its first locally produced XPENG X9 at the 2025 Gaikindo Indonesia International Auto Show (GIIAS). This achievement follows the commencement of operations at XPENG's inaugural overseas production base in Indonesia, realizing the company's strategic localization initiative. Meanwhile, XPENG unveiled its New G6 at GIIAS, just two weeks after its successful European launch, demonstrating the company's accelerated global expansion officially delivered the first locally produced X9 at GIIAS At GIIAS, Xiaopeng He, Chairman and CEO of XPENG, announced via video that XPENG has chosen Indonesia to be the first overseas production base, starting XPENG's global manufacturing deployment. As Southeast Asia's largest automotive market, Indonesia has special strategic significance for XPENG. The establishment of local production in Indonesia, not only represents key milestone in XPENG's global expansion, but also enhances the company's responsiveness to local market needs. It enables more tailored intelligent electric mobility solutions for Southeast Asia, and accelerates the adoption of cutting-edge technologies across the first locally produced XPENG X9 rolled off On July 1, the first locally produced XPENG X9 officially rolled off the production line in Indonesia. This intelligent electric MPV, which seamlessly blends spaceship-inspired design with family-oriented practicality, has already won the favor of 30,000 families worldwide. To demonstrate the capabilities of X9, three Chinese XPENG owners set off from Guangzhou, China on July 5, driving X9 through Laos, Thailand, Malaysia, and Singapore before reaching Jakarta, Indonesia. A nearly 2,485-mile journey that marks the first time a Chinese pure electric MPV traversed Southeast Asia and crossed the equator, and successfully overcame unstable conditions along the way. Equipped with an ultra-comfortable smart cockpit, a leading intelligent driving system, and standard rear-wheel steering, X9 sets a new benchmark in smart mobility. These features align precisely with the needs of Indonesian families. Notably, X9 had already become Hong Kong's best-selling MPV in June, a testament to XPENG's growing momentum in the Asia-Pacific EV market and its emerging leadership potential in the global premium smart EV X9 in Indonesia XPENG also debuts New G6 at GIIAS, which is powered by Qualcomm Snapdragon 8295 chipset and NVIDIA Orin-X processor. It boasts 7.5x the AI processing power and 3x the graphics speed of mainstream competitors in Indonesia, fueling its immersive digital cockpit and advanced driver assistance new G6 made debut at GIIAS "Indonesia embraces some of the world's most respected manufacturing ambitions. Our investment here building facilities, nurturing talent, reflects our commitment to bringing advanced technologies to Indonesia. This is our pledge," said Xiaopeng He, Chairman and CEO of XPENG. Building on this commitment, XPENG will continue to expand its global footprint, driving innovation and fostering sustainable growth. About XPENGFounded in 2014, XPENG is a leading Chinese AI-driven mobility company that designs, develops, manufactures, and markets Smart EVs, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to drive the Smart EV revolution through cutting-edge technology, shaping the future of mobility. To enhance the customer experience, XPENG develops its full-stack advanced driver-assistance system (ADAS) technology and intelligent in-car operating system in-house, along with core vehicle systems such as the powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its Smart EVs are primarily manufactured at its facilities in Zhaoqing and Guangzhou, Guangdong province. XPENG is listed at the New York Stock Exchange (NYSE: XPEV) and Hong Kong Exchange (HKEX: 9868). For more information, please visit Media Enquiries:XPENG PR DepartmentEmail: pr@ XPENG Motors Photos accompanying this announcement are available at A video accompanying this announcement is available athttps:// in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Defiance Launches AIPO: The First ETF Focused on AI Power Infrastructure
Defiance Launches AIPO: The First ETF Focused on AI Power Infrastructure MIAMI, July 25, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance AI & Power Infrastructure ETF (Nasdaq: AIPO). This innovative ETF provides investors with targeted exposure to U.S.-listed companies at the forefront of artificial intelligence (AI) and critical power infrastructure, addressing the surging energy demands of AI technologies through decentralized energy solutions, electrical grids, data centers, and AI hardware. AIPO seeks to track the MarketVector™ US Listed AI and Power Infrastructure Index, offering a passive approach to high-growth themes without the need for margin accounts. AIPO empowers retail investors to capitalize on the intersection of AI innovation and power infrastructure, including sub-themes like nuclear energy generation, data center operations, and AI-enabling semiconductor hardware. Why AI & Power Infrastructure? The explosive growth of AI is straining global energy resources, creating unprecedented opportunities in power generation and infrastructure. Companies in decentralized energy technologies, electric utilities, construction, and AI hardware are poised for expansion as data centers and computing demands escalate. AIPO targets firms deriving at least 50% of revenue from these areas, providing amplified exposure to themes like nuclear power, energy storage, and AI-specific components. This first-mover ETF positions investors to potentially benefit from the high-growth convergence of AI and sustainable power solutions. "Defiance continues to drive innovation in thematic ETFs, and AIPO represents a timely opportunity for investors to access the critical link between AI advancements and power infrastructure," said Sylvia Jablonski, CEO of Defiance ETFs. "As AI technologies require massive energy inputs, companies building the next generation of grids, data centers, and hardware are essential. AIPO offers precise, forward-looking exposure to this dynamic sector, empowering active investors to pursue high-growth potential." About Defiance Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. Our first-mover leveraged single-stock ETFs empower investors to take amplified positions in high-growth companies, providing precise leverage exposure without the need to open a margin account. IMPORTANT DISCLOSURES The Fund's investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read carefully before investing. A hard copy of the prospectuses can be requested by calling 833.333.9383. Defiance ETFs LLC is the ETF sponsor. The Fund's investment adviser is Tidal Investments, LLC ("Tidal" or the "Adviser"). Investing involves risk. Principal loss is possible. As an ETF, the funds may trade at a premium or discount to NAV. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. A portfolio concentrated in a single industry or country, may be subject to a higher degree of risk. Market Risk: The Fund's investments may decline in value due to general market conditions, economic events, or factors affecting specific industries or issuers. Index Tracking Risk: The Fund may not perfectly replicate the performance of the Index due to fees, expenses, and other operational factors. Sector Concentration Risk: Because the Fund may invest heavily in technology, utilities, and energy sectors, it is more vulnerable to adverse developments in these areas. AI and Technology Risk: Companies involved in AI hardware and data centers are subject to rapid innovation cycles, competitive pressures, and regulatory challenges. Energy and Infrastructure Risk: Power generation and utility companies can be impacted by commodity price volatility, regulatory changes, and environmental factors. New Fund Risk: As a newly organized fund, it has no operating history, making it difficult for investors to assess performance or management effectiveness. Passive Investment Risk: The Fund does not actively manage its portfolio and will not take defensive positions if the Index declines. Liquidity Risk: Shares may trade at prices other than NAV, and certain underlying holdings may have limited liquidity. Underlying Index Risk: Errors, changes, or delays in the Index calculation could impact Fund performance. Third-Party Data Risk: The Fund relies on external data providers for Index construction, and inaccuracies or delays may affect tracking. Operational Risk: Failures or errors by service providers, counterparties, or systems could disrupt Fund operations. The MarketVector™ US Listed AI and Power Index (MVAIPO) is a thematic index tracking the performance of companies contributing to critical electrical grid and artificial intelligence infrastructure through nuclear and other decentralized energy technologies, electric equipment and related engineering and construction services, electrical utilities, data center operations, and AI related computing hardware. Note: The Fund is not suitable for all investors and is designed for those who understand thematic sector exposures and are willing to monitor their portfolios. Distributed by Foreside Fund Services, LLC. Contact: David Hanono, info@ 833.333.9383 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
